

IN THE CLAIMS:

Amend the claims as follows.

Claims 1-23. (Canceled)

24. (New) An isolated chemoattractant protein from the C-C chemokine family, wherein said protein is capable of attracting eosinophils and is capable of at least one of inducing eosinophil accumulation and eosinophil activation *in vitro* and *in vivo* wherein said protein is not capable of attracting neutrophils, said protein comprising an amino acid sequence having at least 60% identity with the amino acid sequence of SEQ ID NO: 2, said protein having a molecular weight of 6-16kDa.

25. (New) An isolated chemoattractant protein from the C-C chemokine family, wherein said protein is capable of attracting eosinophils and is capable of at least one of inducing eosinophil accumulation and eosinophil activation *in vitro* and *in vivo*, wherein said protein is not capable of attracting neutrophils, wherein said protein consists of an amino acid sequence having at least 60% identity with the amino acid sequence of SEQ ID NO: 2, and wherein said protein has a molecular weight of 6-16kDa.

26. (New) An isolated chemoattractant protein from the C-C chemokine family, wherein said protein is capable of attracting eosinophils and is capable of at least one of inducing eosinophil accumulation and eosinophil activation *in vitro* and *in vivo*, wherein said protein is not capable of attracting neutrophils, wherein said protein comprises an

amino acid sequence having at least 60% identity with the amino acid sequence set out in SEQ ID NO: 2, and wherein said protein has a molecular weight of 6-16kDa, said at least 60% identity being measured by direct alignment with the BESTFIT program.

27. (New) An isolated chemoattractant polypeptide from the C-C chemokine family produced by a method comprising:

screening a DNA library with a probe consisting of a nucleic acid sequence selected from the group consisting of nucleic acid sequences which encode at least one of SEQ ID NOS: 1 or 2, and obtaining a collection of nucleic acid sequences which bind to said probe;

identifying nucleic acid sequences of said collection which code for amino acid sequences having at least 60% identity with the amino acid sequence of SEQ ID NO: 2, said at least 60% identity being calculated on the basis of overlapping amino acids in corresponding positions of said SEQ ID NO: 2, and obtaining a collection of polypeptides which consist of said amino acid sequences;

identifying at least one polypeptide of said collection of polypeptides having the C-C structure and which are capable of attracting eosinophils and are capable of at least one of inducing eosinophil accumulation and eosinophil activation *in vitro* and *in vivo*, said at least one peptide not being capable of attracting neutrophils; said polypeptide having a molecular weight of from 6kDa to 16kDa.

28. (New) The polypeptide of claim 27 wherein said DNA library comprises a library prepared from allergen-challenged human lung cells.

29. (New) A substantially purified chemoattractant polypeptide from the C-C chemokine family comprising the amino acid sequence of SEQ ID NO: 2.

30. (New) A chemoattractant protein which accomplishes attraction of eosinophils, induction of eosinophil accumulation, and/or activation of eosinophils *in vitro* and *in vivo*, said chemoattractant protein consisting of an amino acid sequence which is at least 60% identical to SEQ ID NO: 2, calculated by the BESTFIT computer program.

31. (New) The chemoattractant protein of claim 30 wherein said sequence is at least 80% identical to SEQ ID NO: 2.

32. (New) The chemoattractant protein of claim 24 wherein said sequence is at least 80% identical to SEQ ID NO: 2.

33. (New) The chemoattractant protein of claim 25 wherein said sequence is at least 80% identical to SEQ ID NO: 2.

34. (New) The chemoattractant protein of claim 26 wherein said sequence is at least 80% identical to SEQ ID NO: 2.

35. (New) The chemoattractant protein of claim 27 wherein said sequence is at least 80% identical to SEQ ID NO: 2.

36. (New) A chemoattractant protein which accomplishes attraction of eosinophils, induction of eosinophil accumulation, and/or activation of eosinophils *in vitro* or *in vivo*, said chemoattractant protein not being capable of attracting neutrophils and said chemoattractant protein comprising an amino acid sequence which is at least 60% identical to SEQ ID NO: 2, calculated by the BESTFIT computer program.

37. (New) The chemoattractant protein of claim 36 wherein said sequence is at least 80% identical to SEQ ID NO: 2.

38. (New) An isolated chemoattractant protein from the C-C chemokine family, wherein said protein is capable of attracting eosinophils and is capable of at least one of inducing eosinophil accumulation and eosinophil activation *in vitro* and *in vivo*, wherein said protein is not capable of attracting neutrophils, said protein comprising an amino acid sequence having at least 60% homology with the amino acid sequence of SEQ ID NO: 2, said protein having a molecular weight of 6-16kDa.

39. (New) An isolated chemoattractant protein from the C-C chemokine family, wherein said protein is capable of attracting eosinophils and is capable of at least one of inducing eosinophil accumulation and eosinophil activation *in vitro* and *in vivo*, wherein said protein is not capable of attracting neutrophils, wherein said protein consists of an amino acid sequence having at least 60% homology with the amino acid sequence of SEQ ID NO: 2, and wherein said protein has a molecular weight of 6-16kDa.

40. (New) An isolated chemoattractant protein from the C-C chemokine family, wherein said protein is capable of attracting eosinophils and is capable of at least one of inducing eosinophil accumulation and eosinophil activation *in vitro* and *in vivo*, wherein said protein is not capable of attracting neutrophils, wherein said protein comprises an amino acid sequence having at least 60% homology with the amino acid sequence set out in SEQ ID NO: 2, and wherein said protein has a molecular weight of 6-16kDa, said at least 60% homology being measured by direct alignment with the BESTFIT program.

41. (New) An isolated chemoattractant polypeptide from the C-C chemokine family produced by a method comprising:

screening a DNA library with a probe consisting of a nucleic acid sequence selected from the group consisting of nucleic acid sequences which encode at least one of SEQ ID NOS: 1 or 2, and obtaining a collection of nucleic acid sequences which bind to said probe;

identifying nucleic acid sequences of said collection which code for amino acid sequences having at least 60% homology with the amino acid sequence of SEQ ID NO: 2, said at least 60% homology being calculated on the basis of overlapping amino acids in corresponding positions of said SEQ ID NO: 2, and obtaining a collection of polypeptides which consist of said amino acid sequences;

identifying at least one polypeptide of said collection of polypeptides having the C-C structure and which are capable of attracting eosinophils and are capable of at least one of inducing eosinophil accumulation and eosinophil activation *in*

vitro and *in vivo*, said at least one peptide not being capable of attracting neutrophils;
said polypeptide having a molecular weight of from 6kDa to 16kDa.

42. (New) The polypeptide of claim 41 wherein said DNA library comprises a library prepared from allergen-challenged human lung cells.

43. (New) A chemoattractant protein which accomplishes attraction of eosinophils, induction of eosinophil accumulation, and/or activation of eosinophils *in vitro* and *in vivo*, said chemoattractant protein consisting of an amino acid sequence which is at least 60% homologous to SEQ ID NO: 2, calculated by the BESTFIT computer program.

44. (New) The chemoattractant protein of claim 43 wherein said sequence is at least 80% homologous to SEQ ID NO: 2.

45. (New) The chemoattractant protein of claim 38 wherein said sequence is at least 80% homologous to SEQ ID NO: 2.

46. (New) The chemoattractant protein of claim 39 wherein said sequence is at least 80% homologous to SEQ ID NO: 2.

47. (New) The chemoattractant protein of claim 40 wherein said sequence is at least 80% homologous to SEQ ID NO: 2.

48. (New) The chemoattractant protein of claim 41 wherein said sequence is at least 80% homologous to SEQ ID NO: 2.

49. (New) A chemoattractant protein which accomplishes attraction of eosinophils, induction of eosinophil accumulation, and/or activation of eosinophils *in vitro* or *in vivo*, said chemoattractant protein not being capable of attracting neutrophils and said chemoattractant protein comprising an amino acid sequence which is at least 60% homologous to SEQ ID NO: 2, calculated by the BESTFIT computer program.

50. (New) The chemoattractant protein of claim 49 wherein said sequence is at least 80% homologous to SEQ ID NO: 2.

51. (New) A method of testing a compound for an inhibitory effect on the activity of the chemoattractant protein of claim 24, comprising assaying inhibition of chemoattraction and/or accumulation and/or activation of eosinophils by an eotaxin.

52. (New) A method for determining the ability of a substance to inhibit eosinophil accumulation and/or activation induced *in vivo* by a chemoattractant protein as claimed in claim 24, wherein the substance is administered to an animal that is pretreated with labelled eosinophils and the chemoattractant protein and the number of labelled eosinophils at a skin site are subsequently determined.